Literature DB >> 35800356

TXNIP knockout improves cardiac function after myocardial infarction by promoting angiogenesis and reducing cardiomyocyte apoptosis.

Jin Wang1, Xue-Jiao Wang1, Yan Zhang1,2, Wen-Juan Shi1, Zhan-Dong Lei1, Xiang-Ying Jiao1.   

Abstract

Background: Myocardial infarction (MI) is a common cause of death. Thioredoxin-interacting protein (TXNIP) expression increases after MI, and it exerts a negative regulatory effect on cardiac function after MI. Our study aimed to investigate the specific regulatory mechanism of TXNIP on angiogenesis and cardiomyocyte apoptosis after MI.
Methods: The TXNIP gene knock-in (TXNIP-KI) and knock-out (TXNIP-KO) mice were generated, respectively. Eight-week-old male TXNIP-KO, TXNIP-KI, and wild type (WT) mice were subjected to MI by permanent ligation of the left anterior descending artery. Cardiomyocyte apoptosis was detected by TUNEL assay on the 4th post-surgery day. The expressions of TXNIP, hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), phosphorylated protein kinase B (p-AKT), p-AMP-activated protein kinase (p-AMPK), cleaved caspase-3, and caspase-3 were detected by Western blot. Quantitative real-time PCR was performed to detect the expression of TXNIP, HIF-1α, VEGF, prolyl hydroxylase (PHD) 1, and factor inhibiting HIF (FIH). In addition, the superoxide dismutase (SOD) activity and malondialdehyde (MDA) level in each group were also measured. On day 7 after MI, the hearts of sacrificed animals were analyzed by immunohistochemistry to assess CD31 expression and determine the density of angiogenesis. One month after treatment, the cardiac functional and structural changes were determined by echocardiography and the level of myocardial fibrosis was observed by Masson staining.
Results: Compared with WT mice, TXNIP-KO mice had a significantly improved cardiac functional recovery after MI, and the proportion of myocardial fibrosis area was dramatically reduced, cardiomyocyte apoptosis was decreased, and angiogenesis was significantly increased; TXNIP-KI mice reversed in these changes. The expression of HIF-1α, p-AKT, and p-AMPK increased after MI in TXNIP-KO mice, and the mRNA expression of PHD 1 and FIH decreased. TXNIP-KI mice reversed in these changes. Conclusions: After MI, TXNIP down-regulated the level of HIF-1α and VEGF, reduced the number of angiogenesis, increased cardiomyocyte apoptosis, and ultimately led to a poor prognosis of ischemic myocardium. TXNIP was a protein with negative effects after MI and was expected to be a target for the prevention and treatment of MI. 2022 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Thioredoxin-interacting protein (TXNIP); angiogenesis; hypoxia-inducible factor-1α (HIF-1α); myocardial infarction (MI)

Year:  2022        PMID: 35800356      PMCID: PMC9253171          DOI: 10.21037/cdt-21-732

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  26 in total

1.  Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins.

Authors:  Parth Patwari; William A Chutkow; Kiersten Cummings; Valerie L R M Verstraeten; Jan Lammerding; Eric R Schreiter; Richard T Lee
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

2.  Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression.

Authors:  A Nishiyama; M Matsui; S Iwata; K Hirota; H Masutani; H Nakamura; Y Takagi; H Sono; Y Gon; J Yodoi
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

3.  A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration.

Authors:  Martin K C Ng; Jenny Wu; Edwin Chang; Bing-yin Wang; Regina Katzenberg-Clark; Akiko Ishii-Watabe; John P Cooke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-02       Impact factor: 8.311

4.  Thioredoxin-interacting protein inhibits hypoxia-inducible factor transcriptional activity.

Authors:  Michael R Farrell; Lynette K Rogers; Yusen Liu; Stephen E Welty; Trent E Tipple
Journal:  Free Radic Biol Med       Date:  2010-08-06       Impact factor: 7.376

5.  miR-126 regulates angiogenesis in myocardial ischemia by targeting HIF-1α.

Authors:  Shuibo Gao; Haixia Gao; Liping Dai; Yongjun Han; Zhen Lei; Xinzhou Wang; Hongbo Chang; Shanshan Liu; Zhentao Wang; Haibin Tong; Hong Wu
Journal:  Exp Cell Res       Date:  2021-11-14       Impact factor: 3.905

Review 6.  Review of the 2017 European Society of Cardiology's Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation and Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Developed in Collaboration with the European Association for Cardio-Thoracic Surgery.

Authors:  Iván J Núñez-Gil; Hynek Riha; Harish Ramakrishna
Journal:  J Cardiothorac Vasc Anesth       Date:  2018-09-27       Impact factor: 2.628

Review 7.  AMPK and HIF signaling pathways regulate both longevity and cancer growth: the good news and the bad news about survival mechanisms.

Authors:  Antero Salminen; Kai Kaarniranta; Anu Kauppinen
Journal:  Biogerontology       Date:  2016-06-03       Impact factor: 4.277

8.  Expression of HIF-2a in clear-cell renal cell carcinoma independently predicts overall survival.

Authors:  Konstantinos Gkagkalidis; Spyridon Kampantais; Georgios Dimitriadis; Victoras Gourvas; Dorothea Kapoukranidou; Maria Mironidou-Tzouveleki
Journal:  Med Mol Morphol       Date:  2020-03-26       Impact factor: 2.309

Review 9.  Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook.

Authors:  Naila Qayyum; Muhammad Haseeb; Moon Suk Kim; Sangdun Choi
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

10.  Acute hyperglycaemia enhances oxidative stress and aggravates myocardial ischaemia/reperfusion injury: role of thioredoxin-interacting protein.

Authors:  Hui Su; Lele Ji; Wenjuan Xing; Wei Zhang; Heping Zhou; Xinhong Qian; Xiaoming Wang; Feng Gao; Xin Sun; Haifeng Zhang
Journal:  J Cell Mol Med       Date:  2013-01-11       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.